Problems and strategies in the research of patient-derived gastric cancer xenograft models
Author:
  • Article
  • | |
  • Metrics
  • |
  • Reference [37]
  • |
  • Related
  • | | |
  • Comments
    Abstract:

    In this paper,we summarize the major problems existing in establishing gastric cancer patient-derived xenograft (PDX) models and its solutions,and introduce its advantages on screening targeted drugs.As many previous research emphasized on individual characteristics too much,we argue that we should pay more attention to the generality of what we are studying in order to analyze the genotype of PDX models before taking a targeted therapy.

    Reference
    [1] Jacome AA, Coutinho AK, Lima EM, et al. Personalized medicine in gastric cancer:Where are we and where are we going?[J]. World J Gastroenterol, 2016, 22(3):1160-1171.
    [2] Lee J, Bass AJ, Ajani JA. Gastric adenocarcinoma:an update on genomics, immune system modulations, and targeted therapy[J]. Am Soc Clin Oncol Educ Book, 2016, 35:104-111.
    [3] Jiang J, Wang DD, Yang M, et al. Comprehensive characterization of chemotherapeutic efficacy on metastases in the established gastric neuroendocrine cancer patient derived xenograft model[J]. Oncotarget, 2015, 6(17):15639-15651.
    [4] Fong EL, Martinez M, Yang J, et al. Hydrogel-based 3D model of patient-derived prostate xenograft tumors suitable for drug screening[J]. Mol Pham, 2014, 7(11):2040-2050.
    [5] Monsma DJ, Cherba DM, Eugster EE, et al. Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms[J]. Am J Cancer Res, 2015, 5(4):1507-1518.
    [6] Cho SY, Kang W, Han JY, et al. An integrative approach to precision cancer medicine using patient-derived xenografts[J]. Mol Cells, 2016, 39(2):77-86.
    [7] Gao H, Korn JM, Ferretti S, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response[J]. Nat Med, 2015, 21(11):1318-1325.
    [8] Monsma DJ, Cherba DM, Richardson PJ, et al. Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance[J]. Pediatr Blood Cancer, 2014, 61(9):1570-1577.
    [9] Zhu Y, Tian T, Li Z, et al. Establishment and characterization of patient-derived tumor xenograft using gastroscopic biopsies in gastric cancer[J]. Scientific reports, 2015, 5:8542.
    [10] Zhang T, Zhang L, Fan S, et al. Patient-derived gastric carcinoma xenograft mouse models faithfully represent human tumor molecular diversity[J]. PLoS One, 2015, 10(7):e0134493.
    [11] Rosfjord E, Lucas J, Li G, et al. Advances in patient-derived tumor xenografts:From target identification to predicting clinical response rates in oncology[J]. Biochem Pharmacol, 2014, 91(2):135-143.
    [12] Guilhamon P, Butcher LM, Presneau N, et al. Assessment of patient-derived tumour xenografts (PDXs) as a discovery tool for cancer epigenomics[J]. Genome Med, 2014, 6(12):116.
    [13] Monsma DJ, Monks NR, Cherba DM, et al. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue[J]. J Transl Med, 2012, 10:125.
    [14] Uronis JM, Osada T, Mccall S, et al. Histological and molecular evaluation of patient-derived colorectal cancer explants[J]. PLoS One, 2012, 7(6):e38422.
    [15] Shultz LD, Saito Y, Najima Y, et al. Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2r gamma(null) humanized mice[J]. Proc Nat Acad Sci U S A, 2010, 107(29):13022.
    [16] Izumchenko E, Meir J, Bedi A, et al. Patient-derived xenografts as tools in pharmaceutical development[J]. Clin Pharmacol Ther, 2016, 99(6):612-621.
    [17] Hiroshima Y, Maawy A, Zhang Y, et al. Patient-derived mouse models of cancer need to be orthotopic in order to evaluate targeted anti-metastatic therapy[J]. Oncotarget, 2016, 7(44):71696-71702.
    [18] Sicklick JK, Leonard SY, Babicky ML, et al. Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor[J]. J Transl Med, 2014, 12:41.
    [19] Yang B, Tuo S, Tuo CW, et al. A liver-metastatic model of human primary gastric lymphoma in nude mice orthotopically constructed by using histologically intact patient specimens[J]. Chin J Cancer, 2010, 29(6):579-584.
    [20] Furukawa T, Kubota T, Watanabe M, et al. Orthotopic transplantation of histologically intact clinical specimens of stomach cancer to nude mice:correlation of metastatic sites in mouse and individual patient donors[J]. Int J Cancer,1993, 53(4):608-612.
    [21] Choi YY, Lee JE, Kim H, et al. Establishment and characterisation of patient-derived xenografts as paraclinical models for gastric cancer[J]. Sci Rep, 2016, 6:22172.
    [22] Zhang L, Liu Y, Wang X, et al. The extent of inflammatory infiltration in primary cancer tissues is associated with lymphomagenesis in immunodeficient mice[J]. Sci Rep, 2015, 5:9447.
    [23] Vockerodt M, Yap LF, Shannon Lowe C, et al. The Epstein-Barr virus and the pathogenesis of lymphoma[J]. 2015, 235(2):312-322.
    [24] You W, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions[J]. J Natl Inst Cancer 2006, 98(14):974-983.
    [25] Fujii E, Kato A, Chen YJ, et al. Characterization of EBV-related lymphoproliferative lesions arising in donor lymphocytes of transplanted human tumor tissues in the NOG mouse[J]. Exp Anim, 2014, 63(3):289-296.
    [26] 胡神保,李小毅,商中华. 人源性异种移植模型在胃肠道恶性肿瘤治疗中的应用[J]. 癌症进展, 2016(10):938-943.
    [27] Javle M, Smyth EC, Chau L. Ramucirumab successfully targeting angiogenesis in gastric cancer[J]. Clin Cancer Res, 2014,20(23):5875-5881.
    [28] Shimoyama S. Unraveling trastuzumab and lapatinib inefficiency in gastric cancer:Future steps (Review)[J]. Mol Clin Oncol, 2014, 2(2):175-181.
    [29] Wang Q, Zhang X, Shen E, et al. The anti-HER3 antibody in combination with trastuzumab exerts synergistic antitumor activity in HER2-positive gastric cancer[J]. Cancer Lett, 2016, 380(1):20-30.
    [30] 田树红,王日超,邢桂兰, 等. 抗VEGF/VEGFR类抗癌药物研发的现状和展望[J]. 中国肿瘤生物治疗杂志, 2015, 22(5):637-645.
    [31] 李克娟, 黄昊, 高苒. 人源肿瘤异种移植模型在精准肿瘤医学中的研究[J]. 中国比较医学杂志, 2017, 27(1):91-98.
    [32] 邱业峰,赵志兵,法云智. 人源性肿瘤异种移植的小鼠模型在肿瘤精准医学中的应用[J]. 实验动物科学, 2016(04):78-83.
    [33] Zhao N, Zhang C, Zhao Y, et al. Optical imaging of gastric cancer with near-infrared heptamethine carbocyanine fluorescence dyes[J]. Oncotarget, 2016, 7(35):57277-57289.
    [34] 胡斌权,陈城明,张同弟,等. 人体肿瘤PDX移植模型的优与劣[J]. 实验动物科学, 2015, 32(05):59-62.
    [35] Choi YY, Cheong JH. Beyond precision surgery:Molecularly motivated precision care for gastric cancer[J]. Eur J Surg Oncol, 2017, 43(5):856-864.
    [36] Wang H, Lu J, Tang J, et al. Establishment of patient-derived gastric cancer xenografts:a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways[J]. BMC Cancer, 2017, 17(1):191.
    [37] Jou E, Rajdev L. Current and emerging therapies in unresectable and recurrent gastric cancer[J]. World J Gastroenterol, 2016, 22(20):4812-4823.
    Related
    Cited by
Get Citation
Related Videos

Share
Article Metrics
  • Abstract:
  • PDF:
  • HTML:
  • Cited by:
History
  • Received:April 11,2017
  • Online: December 16,2017
Article QR Code